Loading…
The association between cinacalcet use and missed in-center hemodialysis treatment rate
Purpose Missed in‐center hemodialysis treatments (MHT) are a general indicator of health status in hemodialysis patients. This analysis was conducted to estimate the association between cinacalcet use and MHT rate. Methods We studied patients receiving hemodialysis and prescription benefits services...
Saved in:
| Published in: | Pharmacoepidemiology and drug safety 2016-11, Vol.25 (11), p.1287-1294 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4900-4ef47ca0e8c08d48c6bf030d8f0cfb8799d33061f0305ae888ed317e395d89e03 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4900-4ef47ca0e8c08d48c6bf030d8f0cfb8799d33061f0305ae888ed317e395d89e03 |
| container_end_page | 1294 |
| container_issue | 11 |
| container_start_page | 1287 |
| container_title | Pharmacoepidemiology and drug safety |
| container_volume | 25 |
| creator | Brunelli, Steven M. Sibbel, Scott Dluzniewski, Paul J. Cooper, Kerry Bensink, Mark E. Bradbury, Brian D. |
| description | Purpose
Missed in‐center hemodialysis treatments (MHT) are a general indicator of health status in hemodialysis patients. This analysis was conducted to estimate the association between cinacalcet use and MHT rate.
Methods
We studied patients receiving hemodialysis and prescription benefits services from a large dialysis organization. Incident cinacalcet users were propensity score matched to controls on 31 demographic, clinical, and laboratory variables. We applied inverse probability (IP) of censoring and crossover weights to account for informative censoring. Weighted negative binomial modeling was used to estimate MHT rates and pooled logistics models were used to estimate the association between cinacalcet use and MHT.
Results
Baseline demographic and clinical variables included serum calcium, phosphorus, parathyroid hormone, and vitamin D use, and were balanced between 15,474 new cinacalcet users and 15,474 matched controls. In an analysis based on intention‐to‐treat principles, 40.8% of cinacalcet users and 46.5% of nonusers were censored. MHT rate was 13% lower among cinacalcet initiators versus controls: IP of censoring weighted incidence rate ratio was 0.87 (95% confidence interval [CI]: 0.84–0.90 p |
| doi_str_mv | 10.1002/pds.4050 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1846409281</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1826709221</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4900-4ef47ca0e8c08d48c6bf030d8f0cfb8799d33061f0305ae888ed317e395d89e03</originalsourceid><addsrcrecordid>eNqN0U1rFTEUBuBBLLZWwV8gATdupp5MkkmylFutSluLVuou5CZnaOp8XJMM9f57M_RaQSi4Ssh5eMnhraoXFI4oQPNm49MRBwGPqgMKWtdUCPl4uQtWK9Hq_eppSjcAZab5k2q_kYy3jVYH1dXlNRKb0uSCzWEayRrzLeJIXBits73DTOZUyOjJEFJCT8JYOxwzRnKNw-SD7bcpJJIj2jyUAYk247Nqr7N9wue787D69v7d5epDffr55OPq7WntuAaoOXZcOguoHCjPlWvXHTDwqgPXrZXU2jMGLV0ehUWlFHpGJTItvNII7LB6fZe7idPPGVM25ZcO-96OOM3JUMVbDrpR9D9o08pCm4W--ofeTHMcyyJFMS5ZIxr-N9DFKaWIndnEMNi4NRTM0ospvZill0Jf7gLn9YD-Hv4pooD6DtyGHrcPBpmL46-7wJ0PKeOve2_jD9NKJoW5Oj8xn75_UaszuDCc_QbQ-KTQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1834732524</pqid></control><display><type>article</type><title>The association between cinacalcet use and missed in-center hemodialysis treatment rate</title><source>Wiley</source><creator>Brunelli, Steven M. ; Sibbel, Scott ; Dluzniewski, Paul J. ; Cooper, Kerry ; Bensink, Mark E. ; Bradbury, Brian D.</creator><creatorcontrib>Brunelli, Steven M. ; Sibbel, Scott ; Dluzniewski, Paul J. ; Cooper, Kerry ; Bensink, Mark E. ; Bradbury, Brian D.</creatorcontrib><description>Purpose
Missed in‐center hemodialysis treatments (MHT) are a general indicator of health status in hemodialysis patients. This analysis was conducted to estimate the association between cinacalcet use and MHT rate.
Methods
We studied patients receiving hemodialysis and prescription benefits services from a large dialysis organization. Incident cinacalcet users were propensity score matched to controls on 31 demographic, clinical, and laboratory variables. We applied inverse probability (IP) of censoring and crossover weights to account for informative censoring. Weighted negative binomial modeling was used to estimate MHT rates and pooled logistics models were used to estimate the association between cinacalcet use and MHT.
Results
Baseline demographic and clinical variables included serum calcium, phosphorus, parathyroid hormone, and vitamin D use, and were balanced between 15,474 new cinacalcet users and 15,474 matched controls. In an analysis based on intention‐to‐treat principles, 40.8% of cinacalcet users and 46.5% of nonusers were censored. MHT rate was 13% lower among cinacalcet initiators versus controls: IP of censoring weighted incidence rate ratio was 0.87 (95% confidence interval [CI]: 0.84–0.90 p < 0.001). In analyses based on as‐treated principles, 72.8% and 61.5% of cinacalcet users and nonusers, respectively, crossed over or were censored. MHT rate was 15% lower among cinacalcet initiators versus controls: IP of censoring/crossover weighted incidence rate ratio was 0.85 (95%CI: 0.82–0.87 p < 0.001).
Conclusions
After controlling for indication and differential censoring, cinacalcet treatment was associated with lower MHT rates, which may reflect better health status. Copyright © 2016 John Wiley & Sons, Ltd.</description><identifier>ISSN: 1053-8569</identifier><identifier>EISSN: 1099-1557</identifier><identifier>DOI: 10.1002/pds.4050</identifier><identifier>PMID: 27346298</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>adherence ; Adult ; Aged ; Calcimimetic Agents - administration & dosage ; Calcium - blood ; Cinacalcet Hydrochloride - administration & dosage ; dialysis ; Health Status ; Hemodialysis ; Humans ; Kidney Failure, Chronic - therapy ; Male ; Medicare ; Middle Aged ; outcomes ; Parathyroid Hormone - blood ; pharmacoepidemiology ; Pharmacology ; Phosphorus - blood ; Renal Dialysis - statistics & numerical data ; Retrospective Studies ; Vitamin D - administration & dosage</subject><ispartof>Pharmacoepidemiology and drug safety, 2016-11, Vol.25 (11), p.1287-1294</ispartof><rights>Copyright © 2016 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4900-4ef47ca0e8c08d48c6bf030d8f0cfb8799d33061f0305ae888ed317e395d89e03</citedby><cites>FETCH-LOGICAL-c4900-4ef47ca0e8c08d48c6bf030d8f0cfb8799d33061f0305ae888ed317e395d89e03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27346298$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brunelli, Steven M.</creatorcontrib><creatorcontrib>Sibbel, Scott</creatorcontrib><creatorcontrib>Dluzniewski, Paul J.</creatorcontrib><creatorcontrib>Cooper, Kerry</creatorcontrib><creatorcontrib>Bensink, Mark E.</creatorcontrib><creatorcontrib>Bradbury, Brian D.</creatorcontrib><title>The association between cinacalcet use and missed in-center hemodialysis treatment rate</title><title>Pharmacoepidemiology and drug safety</title><addtitle>Pharmacoepidemiol Drug Saf</addtitle><description>Purpose
Missed in‐center hemodialysis treatments (MHT) are a general indicator of health status in hemodialysis patients. This analysis was conducted to estimate the association between cinacalcet use and MHT rate.
Methods
We studied patients receiving hemodialysis and prescription benefits services from a large dialysis organization. Incident cinacalcet users were propensity score matched to controls on 31 demographic, clinical, and laboratory variables. We applied inverse probability (IP) of censoring and crossover weights to account for informative censoring. Weighted negative binomial modeling was used to estimate MHT rates and pooled logistics models were used to estimate the association between cinacalcet use and MHT.
Results
Baseline demographic and clinical variables included serum calcium, phosphorus, parathyroid hormone, and vitamin D use, and were balanced between 15,474 new cinacalcet users and 15,474 matched controls. In an analysis based on intention‐to‐treat principles, 40.8% of cinacalcet users and 46.5% of nonusers were censored. MHT rate was 13% lower among cinacalcet initiators versus controls: IP of censoring weighted incidence rate ratio was 0.87 (95% confidence interval [CI]: 0.84–0.90 p < 0.001). In analyses based on as‐treated principles, 72.8% and 61.5% of cinacalcet users and nonusers, respectively, crossed over or were censored. MHT rate was 15% lower among cinacalcet initiators versus controls: IP of censoring/crossover weighted incidence rate ratio was 0.85 (95%CI: 0.82–0.87 p < 0.001).
Conclusions
After controlling for indication and differential censoring, cinacalcet treatment was associated with lower MHT rates, which may reflect better health status. Copyright © 2016 John Wiley & Sons, Ltd.</description><subject>adherence</subject><subject>Adult</subject><subject>Aged</subject><subject>Calcimimetic Agents - administration & dosage</subject><subject>Calcium - blood</subject><subject>Cinacalcet Hydrochloride - administration & dosage</subject><subject>dialysis</subject><subject>Health Status</subject><subject>Hemodialysis</subject><subject>Humans</subject><subject>Kidney Failure, Chronic - therapy</subject><subject>Male</subject><subject>Medicare</subject><subject>Middle Aged</subject><subject>outcomes</subject><subject>Parathyroid Hormone - blood</subject><subject>pharmacoepidemiology</subject><subject>Pharmacology</subject><subject>Phosphorus - blood</subject><subject>Renal Dialysis - statistics & numerical data</subject><subject>Retrospective Studies</subject><subject>Vitamin D - administration & dosage</subject><issn>1053-8569</issn><issn>1099-1557</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqN0U1rFTEUBuBBLLZWwV8gATdupp5MkkmylFutSluLVuou5CZnaOp8XJMM9f57M_RaQSi4Ssh5eMnhraoXFI4oQPNm49MRBwGPqgMKWtdUCPl4uQtWK9Hq_eppSjcAZab5k2q_kYy3jVYH1dXlNRKb0uSCzWEayRrzLeJIXBits73DTOZUyOjJEFJCT8JYOxwzRnKNw-SD7bcpJJIj2jyUAYk247Nqr7N9wue787D69v7d5epDffr55OPq7WntuAaoOXZcOguoHCjPlWvXHTDwqgPXrZXU2jMGLV0ehUWlFHpGJTItvNII7LB6fZe7idPPGVM25ZcO-96OOM3JUMVbDrpR9D9o08pCm4W--ofeTHMcyyJFMS5ZIxr-N9DFKaWIndnEMNi4NRTM0ospvZill0Jf7gLn9YD-Hv4pooD6DtyGHrcPBpmL46-7wJ0PKeOve2_jD9NKJoW5Oj8xn75_UaszuDCc_QbQ-KTQ</recordid><startdate>201611</startdate><enddate>201611</enddate><creator>Brunelli, Steven M.</creator><creator>Sibbel, Scott</creator><creator>Dluzniewski, Paul J.</creator><creator>Cooper, Kerry</creator><creator>Bensink, Mark E.</creator><creator>Bradbury, Brian D.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>201611</creationdate><title>The association between cinacalcet use and missed in-center hemodialysis treatment rate</title><author>Brunelli, Steven M. ; Sibbel, Scott ; Dluzniewski, Paul J. ; Cooper, Kerry ; Bensink, Mark E. ; Bradbury, Brian D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4900-4ef47ca0e8c08d48c6bf030d8f0cfb8799d33061f0305ae888ed317e395d89e03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>adherence</topic><topic>Adult</topic><topic>Aged</topic><topic>Calcimimetic Agents - administration & dosage</topic><topic>Calcium - blood</topic><topic>Cinacalcet Hydrochloride - administration & dosage</topic><topic>dialysis</topic><topic>Health Status</topic><topic>Hemodialysis</topic><topic>Humans</topic><topic>Kidney Failure, Chronic - therapy</topic><topic>Male</topic><topic>Medicare</topic><topic>Middle Aged</topic><topic>outcomes</topic><topic>Parathyroid Hormone - blood</topic><topic>pharmacoepidemiology</topic><topic>Pharmacology</topic><topic>Phosphorus - blood</topic><topic>Renal Dialysis - statistics & numerical data</topic><topic>Retrospective Studies</topic><topic>Vitamin D - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brunelli, Steven M.</creatorcontrib><creatorcontrib>Sibbel, Scott</creatorcontrib><creatorcontrib>Dluzniewski, Paul J.</creatorcontrib><creatorcontrib>Cooper, Kerry</creatorcontrib><creatorcontrib>Bensink, Mark E.</creatorcontrib><creatorcontrib>Bradbury, Brian D.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Pharmacoepidemiology and drug safety</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brunelli, Steven M.</au><au>Sibbel, Scott</au><au>Dluzniewski, Paul J.</au><au>Cooper, Kerry</au><au>Bensink, Mark E.</au><au>Bradbury, Brian D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The association between cinacalcet use and missed in-center hemodialysis treatment rate</atitle><jtitle>Pharmacoepidemiology and drug safety</jtitle><addtitle>Pharmacoepidemiol Drug Saf</addtitle><date>2016-11</date><risdate>2016</risdate><volume>25</volume><issue>11</issue><spage>1287</spage><epage>1294</epage><pages>1287-1294</pages><issn>1053-8569</issn><eissn>1099-1557</eissn><abstract>Purpose
Missed in‐center hemodialysis treatments (MHT) are a general indicator of health status in hemodialysis patients. This analysis was conducted to estimate the association between cinacalcet use and MHT rate.
Methods
We studied patients receiving hemodialysis and prescription benefits services from a large dialysis organization. Incident cinacalcet users were propensity score matched to controls on 31 demographic, clinical, and laboratory variables. We applied inverse probability (IP) of censoring and crossover weights to account for informative censoring. Weighted negative binomial modeling was used to estimate MHT rates and pooled logistics models were used to estimate the association between cinacalcet use and MHT.
Results
Baseline demographic and clinical variables included serum calcium, phosphorus, parathyroid hormone, and vitamin D use, and were balanced between 15,474 new cinacalcet users and 15,474 matched controls. In an analysis based on intention‐to‐treat principles, 40.8% of cinacalcet users and 46.5% of nonusers were censored. MHT rate was 13% lower among cinacalcet initiators versus controls: IP of censoring weighted incidence rate ratio was 0.87 (95% confidence interval [CI]: 0.84–0.90 p < 0.001). In analyses based on as‐treated principles, 72.8% and 61.5% of cinacalcet users and nonusers, respectively, crossed over or were censored. MHT rate was 15% lower among cinacalcet initiators versus controls: IP of censoring/crossover weighted incidence rate ratio was 0.85 (95%CI: 0.82–0.87 p < 0.001).
Conclusions
After controlling for indication and differential censoring, cinacalcet treatment was associated with lower MHT rates, which may reflect better health status. Copyright © 2016 John Wiley & Sons, Ltd.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>27346298</pmid><doi>10.1002/pds.4050</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1053-8569 |
| ispartof | Pharmacoepidemiology and drug safety, 2016-11, Vol.25 (11), p.1287-1294 |
| issn | 1053-8569 1099-1557 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1846409281 |
| source | Wiley |
| subjects | adherence Adult Aged Calcimimetic Agents - administration & dosage Calcium - blood Cinacalcet Hydrochloride - administration & dosage dialysis Health Status Hemodialysis Humans Kidney Failure, Chronic - therapy Male Medicare Middle Aged outcomes Parathyroid Hormone - blood pharmacoepidemiology Pharmacology Phosphorus - blood Renal Dialysis - statistics & numerical data Retrospective Studies Vitamin D - administration & dosage |
| title | The association between cinacalcet use and missed in-center hemodialysis treatment rate |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T19%3A02%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20association%20between%20cinacalcet%20use%20and%20missed%20in-center%20hemodialysis%20treatment%20rate&rft.jtitle=Pharmacoepidemiology%20and%20drug%20safety&rft.au=Brunelli,%20Steven%20M.&rft.date=2016-11&rft.volume=25&rft.issue=11&rft.spage=1287&rft.epage=1294&rft.pages=1287-1294&rft.issn=1053-8569&rft.eissn=1099-1557&rft_id=info:doi/10.1002/pds.4050&rft_dat=%3Cproquest_cross%3E1826709221%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4900-4ef47ca0e8c08d48c6bf030d8f0cfb8799d33061f0305ae888ed317e395d89e03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1834732524&rft_id=info:pmid/27346298&rfr_iscdi=true |